Drug repurposing for COVID-19: could vitamin C combined with glycyrrhizic acid be at play by the findings of Li et al.'s database-based network pharmacology analysis?
Brief Bioinform
; 22(2): 1508-1510, 2021 03 22.
Article
in English
| MEDLINE | ID: covidwho-1343639
ABSTRACT
The outbreak and pandemic of SARS-CoV-2 in 2019 has caused a severe public health burden and will challenge global health for the future. The discovery and mechanistic investigation of drugs against Coronavirus disease 2019 (COVID-19) is in deadly demand. The paper published by Li and colleagues proposed the hypothesis that vitamin C combined with glycyrrhizic acid in treating COVID-19 and its mechanistic investigation was performed by a database-based network pharmacology. In this letter, we present critical comments on the limitations and insufficiencies involved, from both the perspective of network pharmacology and current evidence on COVID-19.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Ascorbic Acid
/
Glycyrrhizic Acid
/
Drug Repositioning
/
Databases, Pharmaceutical
/
COVID-19 Drug Treatment
Limits:
Humans
Language:
English
Journal:
Brief Bioinform
Journal subject:
Biology
/
Medical Informatics
Year:
2021
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS